Loading...
Market
Prodia's next major milestone by end of 2024?
2
Resolution / Starting Odds
Achieves 50% cost reduction • 25%
Secures additional funding round • 25%
Integrates with 5 major AI platforms • 25%
Launches new REST API • 25%
Official announcements from Prodia and industry reports
Story
Prodia Raises $15 Million to Develop Scalable AI Solutions Using Distributed GPUs
Jul 2, 2024, 01:51 PM
Prodia has raised $15 million in a funding round led by Dragonfly XYZ to develop scalable and affordable AI solutions using distributed GPU cloud technology. Prodia’s distributed GPU cloud technology reduces costs by 50%-90% and speeds up AI generation by an average of 400%. The funding will support Prodia’s mission to revolutionize AI inference and provide a seamless REST API for users. This investment highlights the growing intersection of crypto and AI, with Prodia emerging as a key player in this space.
View original story
Similar markets
Phase 3 trial completion • 25%
Regulatory approval • 25%
Commercial launch • 25%
Partnership or acquisition • 25%
Starts production of 1,000 Starships annually • 33%
Reaches serialized production of Falcon 9's second stage • 33%
Completes construction and begins operations • 34%
Progress to Phase 2 • 25%
Significant efficacy results • 25%
Safety concerns emerge • 25%
No significant milestone • 25%
Completion of site investigations • 25%
Submission of application under the ADVANCE Act • 25%
Approval of application under the ADVANCE Act • 25%
No major milestone achieved • 25%
Preclinical success • 25%
Phase 1 completion • 25%
Phase 2 completion • 25%
Phase 3 initiation • 25%
Secures Series A funding • 25%
Announces major partnership • 25%
Publishes groundbreaking research • 25%
Other • 25%
New clinical trial initiation • 25%
Partnership with another pharma company • 25%
FDA approval • 25%
Acquisition by Lilly • 25%
Human clinical trials begin • 25%
Partnership with major healthcare provider • 25%
Patent granted for technology • 25%
No significant milestone achieved • 25%
Phase 2 completion • 25%
Phase 3 initiation • 25%
Regulatory approval submission • 25%
No significant milestone • 25%
Publishes in Nature or Science • 25%
Partners with a top 10 pharmaceutical company • 25%
Releases a new version of Chai-1 • 25%
None of the above • 25%
Scalability improvements • 25%
Security enhancements • 25%
User interface upgrades • 25%
Other • 25%